WHAT:
Rho, a full-service contract research organization (CRO), will highlight its clinical trial expertise during the Toxicology Roundtable 2017 conference, being held October 1-4 in Montreal, Quebec.
Dana Minnick, senior research scientist at Rho, will be presenting “Risk versus Benefit: Abbreviated nonclinical toxicology programs for rare diseases.” In this presentation, she will provide tips and strategies for obtaining accurate results quickly.
Rho focuses on helping pharmaceutical and biotechnology companies bring their products to market through high-quality clinical research services, including clinical operations, project management, data management, data standards and biostatistics, with extensive experience in pain products.
WHO:
Rho expert at Toxicology Roundtable 2017:
Dana Minnick, senior research scientist, Rho
WHEN:
October 1-4, 2017
WHERE:
Le Saint-Sulpice Hôtel Montréal
414 St Sulpice St.
Montreal, QC H2Y 2V5, Canada
DETAILS:
For media inquiries, please contact Bernadette Miller at Largemouth Communications, (703) 297-5992, bernadette@largemouthpr.com.
ABOUT:
Rho, a privately-held, contract research organization (CRO) located in Chapel Hill, NC, provides a full range of clinical research services across the entire drug development process. For 33 years, Rho has been a trusted partner to some of the industry’s leading pharmaceutical, biotechnology, and medical device companies as well as academic and government organizations. Our commitment to excellence, our innovative technologies, and our therapeutic expertise accelerate time to market, maximize returns on investment, and lead to an exceptional customer experience. For more information, please visit www.rhoworld.com and follow us on Twitter.
